| Ident. | Authors (with country if any) | Title |
|---|
| 000128 |
M. S. Lee [Corée du Sud] ; C. H. Lyoo [Corée du Sud] ; Y. H. Ryu [Corée du Sud] ; H. S. Lim [Corée du Sud] ; C. M. Nam [Corée du Sud] ; H. S. Kim [Corée du Sud] ; J. O. Rinne [Finlande] | The effect of age on motor deficits and cerebral glucose metabolism of Parkinson’s disease |
| 000130 |
Lise Hounsgaard [Danemark] ; Birthe Pedersen [Danemark] ; Lis Wagner [Danemark] | The daily living for informal caregivers with a partner with Parkinson’s disease – an interview study of women’s experiences of care decisions and self‐management |
| 000152 |
F. Valldeoriola ; C. Coronell [Espagne] ; C. Pont ; M. T. Buongiorno ; A. Cámara ; C. Gaig ; Y. Compta | Socio‐demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESON study |
| 000174 |
M. Matinolli [Finlande] ; J. T. Korpelainen [Finlande] ; K. A. Sotaniemi [Finlande] ; V. V. Myllyl [Finlande] ; R. Korpelainen [Finlande] | Recurrent falls and mortality in Parkinson’s disease: a prospective two‐year follow‐up study |
| 000231 |
Beate Winner [États-Unis, Allemagne] ; Zacharias Kohl [Allemagne] ; Fred H. Gage [États-Unis] | Neurodegenerative disease and adult neurogenesis |
| 000270 |
Anita Haahr [Danemark] ; Marit Kirkevold [Norvège] ; Elisabeth O. C. Hall [Danemark] ; Karen Stergaard [Danemark] | Living with advanced Parkinson’s disease: a constant struggle with unpredictability |
| 000273 |
E. Pascale [Italie] ; E. Passarelli [Italie] ; C. Purcaro [Italie] ; A. R. Vestri [Italie] ; A. Fakeri [Italie] ; R. Guglielmi [Italie] ; F. Passarelli [Italie] ; G. Meco [Italie] | Lack of association between IL‐1β, TNF‐α, and IL‐10 gene polymorphisms and sporadic Parkinson’s disease in an Italian cohort |
| 000284 |
Maria Papathanou [Suède] ; Sarah Rose [Royaume-Uni] ; Andrew Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats |
| 000289 |
Guadalupe Soria [Espagne] ; Esther Aguilar [Espagne] ; Raúl Tudela [Espagne] ; Joaquim Mullol [Espagne] ; Anna M. Planas [Espagne] ; Concepci Marin [Espagne] | In vivo magnetic resonance imaging characterization of bilateral structural changes in experimental Parkinson’s disease: a T2 relaxometry study combined with longitudinal diffusion tensor imaging and manganese‐enhanced magnetic resonance imaging in the 6‐hydroxydopamine rat model |
| 000328 |
F. Stocchi [Italie] ; J. M. Rabey [Israël] | Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease |
| 000335 |
N. A. Aziz [Pays-Bas] ; H. Pijl [Pays-Bas] ; M. Frölich [Pays-Bas] ; F. Roelfsema [Pays-Bas] ; R. A. C. Roos [Pays-Bas] | Diurnal Secretion Profiles of Growth Hormone, Thyrotrophin and Prolactin in Parkinson’s Disease |
| 000340 |
M. Iijima [Japon] ; T. Kobayakawa ; S. Saito ; M. Osawa [Japon] ; Y. Tsutsumi [Japon] ; S. Hashimoto [Japon] ; S. Uchiyama [Japon] | Differences in odor identification among clinical subtypes of Parkinson’s disease |
| 000346 |
J. C. Dachsel [États-Unis] ; C. Wider [États-Unis, Suisse] ; C. Vilari O-Güell [États-Unis] ; J. O. Aasly [Norvège] ; A. Rajput [Canada] ; A. H. Rajput [Canada] ; T. Lynch [Irlande (pays)] ; D. Craig [Royaume-Uni] ; A. Krygowska-Wajs [Pologne] ; B. Jasinska-Myga [États-Unis] ; G. Opala ; M. Barcikowska [Pologne] ; K. Czyzewski [Pologne] ; R. Wu [Taïwan] ; M. G. Heckman [États-Unis] ; R. J. Uitti [États-Unis] ; Z. K. Wszolek [États-Unis] ; M. J. Farrer [États-Unis] ; O. A. Ross [États-Unis] | Death‐associated protein kinase 1 variation and Parkinson’s disease |
| 000352 |
Bomin Shim [États-Unis] ; Lawrence R. Landerman [États-Unis] ; Linda L. Davis [États-Unis] | Correlates of care relationship mutuality among carers of people with Alzheimer’s and Parkinson’s disease |
| 000360 |
Y. Oh [Corée du Sud] ; J. Kim [Corée du Sud] ; S. Chung [Corée du Sud] ; I. Song [Corée du Sud] ; Y. Kim [Corée du Sud] ; Y. Kim [Corée du Sud] ; K. Lee [Corée du Sud] | Color vision in Parkinson’s disease and essential tremor |
| 000369 |
F. Escamilla-Sevilla ; M. J. Pérez-Navarro ; M. Mu Oz-Pasadas ; C. Sáez-Zea ; M. Jouma-Katati ; G. Piédrola-Maroto ; A. Ramírez-Navarro [Espagne] ; A. Mínguez-Castellanos | Change of the melanocortin system caused by bilateral subthalamic nucleus stimulation in Parkinson’s disease |
| 000370 |
A. H. V. Schapira [Royaume-Uni] | Challenges to the development of disease‐modifying therapies in Parkinson’s disease |
| 000375 |
H. Oka [Japon] ; C. Toyoda [Japon] ; M. Yogo [Japon] ; S. Mochio [Japon] | Cardiovascular dysautonomia in de novo Parkinson’s disease without orthostatic hypotension |
| 000403 |
G-M. Hariz [Suède] ; L. Forsgren [Suède] | Activities of daily living and quality of life in persons with newly diagnosed Parkinson’s disease according to subtype of disease, and in comparison to healthy controls |
| 000410 |
Naomi Nelson [États-Unis] ; Dorothy Wong [États-Unis] ; Eugene Lai [États-Unis] | A self‐management program for veterans and spouses living with Parkinson’s disease |
| 000412 |
Saskia Van Stockum [Nouvelle-Zélande] ; Michael R. Macaskill [Nouvelle-Zélande] ; Daniel Myall [Nouvelle-Zélande] ; Tim J. Anderson [Nouvelle-Zélande] | A perceptual discrimination task abnormally facilitates reflexive saccades in Parkinson’s disease |
| 000414 |
N. Tambasco ; V. Belcastro [Italie] ; P. Sarchielli ; P. Floridi ; L. Pierguidi [Italie] ; C. Menichetti [Italie] ; A. Castrioto ; P. Chiarini ; L. Parnetti ; P. Eusebi [Italie] ; P. Calabresi [Italie] ; A. Rossi | A magnetization transfer study of mild and advanced Parkinson’s disease |
| 000488 |
Li Rebekah Feng [États-Unis] ; Howard J. Federoff [États-Unis] ; Stefano Vicini [États-Unis] ; Kathleen A. Maguire-Zeiss [États-Unis] | α‐Synuclein mediates alterations in membrane conductance: a potential role for α‐synuclein oligomers in cell vulnerability |
| 000510 |
H. Vefring [Norvège] ; K. Haugarvoll [Norvège] ; O. Tysnes [Norvège] ; J. P. Larsen [Norvège] ; M. W. Kurz [Norvège] | The role of APOE alleles in incident Parkinson’s disease. The Norwegian ParkWest Study |
| 000517 |
Kitty M. Suddick ; Simon Chambers [Royaume-Uni] | The lived experience of sleep disturbance in people with Parkinson’s disease |
| 000529 |
E. Wang [République populaire de Chine] ; Y. Sun [République populaire de Chine] ; J. Guo [République populaire de Chine] ; X. Gao [République populaire de Chine] ; J. Hu [République populaire de Chine] ; L. Zhou [République populaire de Chine] ; J. Hu [République populaire de Chine] ; C. Jiang [République populaire de Chine] | Tetranectin and apolipoprotein A‐I in cerebrospinal fluid as potential biomarkers for Parkinson’s disease |
| 000542 |
I. Mateo [Espagne] ; J. Infante [Espagne] ; P. Sánchez-Juan [Espagne] ; I. García-Gorostiaga [Espagne] ; E. Rodríguez-Rodríguez [Espagne] ; J. L. Vázquez-Higuera [Espagne] ; J. Berciano [Espagne] ; O. Combarros [Espagne] | Serum heme oxygenase‐1 levels are increased in Parkinson’s disease but not in Alzheimer’s disease |
| 000556 |
Romulo Fuentes [États-Unis] ; Per Petersson [Suède] ; Miguel A. L. Nicolelis [États-Unis, Brésil] | Restoration of locomotive function in Parkinson’s disease by spinal cord stimulation: mechanistic approach |
| 000594 |
C. Vossius [Norvège] ; O. B. Nilsen [Norvège] ; J. P. Larsen [Norvège] | Parkinson’s disease and hospital admissions: frequencies, diagnoses and costs |
| 000628 |
P. Barone [Italie] | Neurotransmission in Parkinson’s disease: beyond dopamine |
| 000630 |
Xiao-Qing Tang [République populaire de Chine] ; Yu-Juan Li ; Jing Zhao ; Xing-Tian Shen ; Chun-Tao Yang ; Li-Li Fan ; Bi Hu ; Yuan-Jian Li ; Duan-Fan Liao [République populaire de Chine] | Neuroprotective effect of asymmetric dimethylarginine against 1‐methyl‐4‐phenylpyridinium ion‐induced damage in PC12 cells |
| 000650 |
E. L. Johnsen ; N. Sunde ; P. H. Mogensen [Danemark] ; K. Stergaard | MRI verified STN stimulation site – gait improvement and clinical outcome |
| 000658 |
Y. Winter ; M. Balzer-Geldsetzer ; A. Spottke [Allemagne] ; J. P. Reese ; E. Baum ; J. Klotsche ; J. Rieke ; A. Simonow [Allemagne] ; K. Eggert ; W. H. Oertel ; R. Dodel | Longitudinal study of the socioeconomic burden of Parkinson’s disease in Germany |
| 000672 |
C. Rodriguez-Blazquez [Espagne] ; M. J. Forjaz [Espagne] ; B. Frades-Payo [Espagne] ; J. De Pedro-Cuesta [Espagne] ; P. Martinez-Martin [Espagne] | Independent validation of the scales for outcomes in Parkinson’s disease‐autonomic (SCOPA‐AUT) |
| 000688 |
V. Belcastro [Italie] ; L. Pierguidi [Italie] ; A. Castrioto [Italie] ; C. Menichetti [Italie] ; G. Gorgone [Italie] ; R. Ientile ; F. Pisani [Italie] ; A. Rossi [Italie] ; P. Calabresi [Italie] ; N. Tambasco [Italie] | Hyperhomocysteinemia recurrence in levodopa‐treated Parkinson’s disease patients |
| 000715 |
A. G. Beiske [Norvège] ; E. Svensson [Norvège] | Fatigue in Parkinson’s disease: a short update |
| 000721 |
Y. Cai [République populaire de Chine] ; S. Liu [République populaire de Chine] ; R. B. Sothern [États-Unis] ; S. Xu [République populaire de Chine] ; P. Chan [République populaire de Chine] | Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson’s disease |
| 000722 |
M. Soilu-H Nninen ; E. Broberg ; M. Röytt ; P. Mattila ; J. Rinne [Finlande] ; V. Hukkanen [Finlande] | Expression of LIF and LIF receptor beta in Alzheimer’s and Parkinson’s diseases |
| 000727 |
Jens Clausen [Allemagne] | Ethical brain stimulation – neuroethics of deep brain stimulation in research and clinical practice |
| 000733 |
H. Reichmann ; W. H. Jost [Allemagne] | Efficacy and tolerability of rasagiline in daily clinical use – a post‐marketing observational study in patients with Parkinson’s disease |
| 000741 |
David Devos [France] ; L. Defebvre [France] ; R. Bordet [France] | Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease |
| 000758 |
C. Tai ; R. Wu ; C. Lin ; M. Pan ; Y. Chen ; H. Liu ; H. Lu ; C. Tsai ; S. Tseng [Taïwan] | Deep brain stimulation therapy for Parkinson’s disease using frameless stereotaxy: comparison with frame‐based surgery |
| 000760 |
M. Rossi ; E. R. Gerschcovich ; D. De Achaval ; S. Perez-Lloret ; D. Cerquetti ; A. Cammarota ; M. Inés Nouzeilles ; R. Fahrer [Argentine] ; M. Merello ; R. Leiguarda | Decision‐making in Parkinson’s disease patients with and without pathological gambling |
| 000766 |
Ayse Ulusoy [Suède] ; Fabia Febbraro [Danemark] ; Poul H. Jensen [Danemark] ; Deniz Kirik [Suède] ; Marina Romero-Ramos [Suède, Danemark] | Co‐expression of C‐terminal truncated alpha‐synuclein enhances full‐length alpha‐synuclein‐induced pathology |
| 000784 |
K. Ishibashi [Japon] ; K. Kanemaru [Japon] ; Y. Saito [Japon] ; S. Murayama [Japon] ; K. Oda [Japon] ; K. Ishiwata [Japon] ; H. Mizusawa [Japon] ; K. Ishii [Japon] | Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson’s disease |
| 000786 |
I. Leiknes [Norvège] ; O. Tysnes [Norvège] ; D. Aarsland [Norvège] ; J. P. Larsen [Norvège] | Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson’s disease: the Norwegian ParkWest study |
| 000801 |
Lena F. Burbulla [Allemagne] ; Guido Krebiehl [Allemagne] ; Rejko Krüger [Allemagne] | Balance is the challenge – The impact of mitochondrial dynamics in Parkinson’s disease |
| 000803 |
F. Hu ; J. Xi ; J. Guo ; L. Yu ; L. Liu ; X. He ; Z. Liu [République populaire de Chine] ; X. Zou ; Y. Xu | Association of the glucocerebrosidase N370S allele with Parkinson’s disease in two separate Chinese Han populations of mainland China |
| 000804 |
C. Wider [États-Unis] ; C. Vilari O-Güell [États-Unis] ; B. Jasinska-Myga [États-Unis, Pologne] ; M. G. Heckman [États-Unis] ; A. I. Soto-Ortolaza [États-Unis] ; S. A. Cobb [États-Unis] ; J. O. Aasly [Norvège] ; J. M. Gibson [Irlande (pays)] ; T. Lynch [Irlande (pays)] ; R. J. Uitti [États-Unis] ; Z. K. Wszolek [États-Unis] ; M. J. Farrer [États-Unis] ; O. A. Ross [États-Unis] | Association of the MAPT locus with Parkinson’s disease |
| 000808 |
M. J. Forjaz [Espagne] ; A. Ayala [Espagne] ; C. Rodriguez-Blazquez [Espagne] ; B. Frades-Payo [Espagne] ; P. Martinez-Martin [Espagne] | Assessing autonomic symptoms of Parkinson’s disease with the SCOPA‐AUT: a new perspective from Rasch analysis |
| 000810 |
O. Tysnes [Norvège] ; B. Müller [Norvège] ; J. P. Larsen [Norvège] | Are dysautonomic and sensory symptoms present in early Parkinson’s disease? |
| 000811 |
D. Uluduz ; Ö. Ertürk ; G. Kenangil ; S. Özekmekçi ; S. Ertan ; H. Apaydin ; E. Erginöz [Turquie] | Apraxia in Parkinson’s disease and multiple system atrophy |
| 000827 |
K. Tanaka ; Y. Miyake ; W. Fukushima ; S. Sasaki [Japon] ; C. Kiyohara ; Y. Tsuboi ; T. Yamada ; T. Oeda ; T. Miki ; N. Kawamura ; N. Sakae ; H. Fukuyama ; Y. Hirota ; M. Nagai [Japon] | Active and passive smoking and risk of Parkinson’s disease |
| 000842 |
P. Borghammer [Danemark] ; K. Stergaard [Danemark] ; P. Cumming [Allemagne] ; A. Gjedde [Danemark] ; A. Rodell [Danemark] ; N. Hall [Danemark] ; M. M. Chakravarty [Danemark, États-Unis] | A deformation‐based morphometry study of patients with early‐stage Parkinson’s disease |
| 000931 |
Thibaud Lebouvier [France] ; Tanguy Chaumette [France] ; Sébastien Paillusson [France] ; Charles Duyckaerts [France] ; Stanislas Bruley Des Varannes [France] ; Michel Neunlist [France] ; Pascal Derkinderen [France] | The second brain and Parkinson’s disease |
| 000932 |
J. H. Roh [Corée du Sud] ; B. Kim [Corée du Sud] ; J. Jang [Corée du Sud] ; W. Seo [Corée du Sud] ; S. Lee [Corée du Sud] ; J. H. Kim [Corée du Sud] ; K. Oh [Corée du Sud] ; K. Park [Corée du Sud] ; D. Lee [Corée du Sud] ; S. Koh [Corée du Sud] | The relationship of pain and health‐related quality of life in Korean patients with Parkinson’s disease |
| 000937 |
M. M. Wickremaratchi [Royaume-Uni] ; Y. Ben-Shlomo [Royaume-Uni] ; H. R. Morris [Royaume-Uni] | The effect of onset age on the clinical features of Parkinson’s disease |
| 000953 |
T. D. H Lbig [France, États-Unis] ; W. Tse [États-Unis] ; P. G. Frisina [États-Unis] ; B. R. Baker [États-Unis] ; E. Hollander [États-Unis] ; H. Shapiro [États-Unis] ; M. Tagliati [États-Unis] ; W. C. Koller [États-Unis] ; C. W. Olanow [États-Unis] | Subthalamic deep brain stimulation and impulse control in Parkinson’s disease |
| 000999 |
C. Vossius ; O. B. Nilsen [Norvège] ; J. P. Larsen | Parkinson’s disease and nursing home placement: the economic impact of the need for care |
| 000A15 |
J. Coste [France] ; L. Ouchchane [France] ; L. Sarry [France] ; P. Derost [France] ; F. Durif [France] ; J. Gabrillargues [France] ; S. Hemm [France] ; J. J. Lemaire [France] | New electrophysiological mapping combined with MRI in parkinsonian’s subthalamic region |
| 000A31 |
M. Matinolli [Finlande] ; J. T. Korpelainen [Finlande] ; R. Korpelainen [Finlande] ; K. A. Sotaniemi [Finlande] ; V. Matinolli [Finlande] ; V. V. Myllyl [Finlande] | Mobility and balance in Parkinson’s disease: a population‐based study |
| 000A73 |
Na K. Kim [Corée du Sud] ; Byung H. Choi [Corée du Sud] ; Xian Huang [Corée du Sud] ; Brian J. Snyder [Canada] ; Shefqat Bukhari [Canada] ; Tae-Ho Kong [Corée du Sud] ; Hyeonseon Park [Corée du Sud] ; Hyung C. Park [Corée du Sud] ; So R. Park [Corée du Sud] ; Yoon Ha [Corée du Sud] | Granulocyte–macrophage colony‐stimulating factor promotes survival of dopaminergic neurons in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced murine Parkinson’s disease model |
| 000A80 |
B. Jasinska-Myga [États-Unis, Pologne] ; C. Wider [États-Unis] ; G. Opala [Pologne] ; A. Krygowska-Wajs [Pologne] ; M. Barcikowska [Pologne] ; K. Czyzewski [Pologne] ; M. Baker [États-Unis] ; R. Rademakers [États-Unis] ; R. J. Uitti [États-Unis] ; M. J. Farrer [États-Unis] ; O. A. Ross [États-Unis] ; Z. K. Wszolek [États-Unis] | GRN 3′UTR+78 C>T is not associated with risk for Parkinson’s disease |
| 000A84 |
M. H. Nilsson [Suède] ; P. Hagell [Suède] | Freezing of Gait Questionnaire: validity and reliability of the Swedish version |
| 000B01 |
C. Marin [Espagne] ; E. Aguilar [Espagne] ; G. Mengod [Espagne] ; R. Cortés [Espagne] ; J. A. Obeso [Espagne] | Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats |
| 000B04 |
H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni] | Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis |
| 000B08 |
C. G. Bachmann ; A. Zapf [Allemagne] ; E. Brunner [Allemagne] ; C. Trenkwalder | Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias |
| 000B30 |
D. Nyholm [Suède] ; R. Constantinescu [Suède] ; B. Holmberg [Suède] ; N. Dizdar [Suède] ; H. Askmark [Suède] | Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations |
| 000B34 |
E. Elgh ; M. Domellöf ; J. Linder ; M. Edström ; H. Stenlund [Suède] ; L. Forsgren | Cognitive function in early Parkinson’s disease: a population‐based study |
| 000B62 |
M. M. Lewis [États-Unis] ; A. B. Smith [États-Unis] ; M. Styner [États-Unis] ; H. Gu [États-Unis] ; R. Poole [États-Unis] ; H. Zhu [États-Unis] ; Y. Li [États-Unis] ; X. Barbero [États-Unis] ; S. Gouttard [États-Unis] ; M. J. Mckeown [Canada] ; R. B. Mailman [États-Unis] ; X. Huang [États-Unis] | Asymmetrical lateral ventricular enlargement in Parkinson’s disease |
| 000C23 |
I. Midi [Turquie] ; M. Dogan [Turquie] ; M. Koseoglu [Turquie] ; G. Can [Turquie] ; M. A. Sehitoglu [Turquie] ; D. I. Gunal [Turquie] | Voice abnormalities and their relation with motor dysfunction in Parkinson’s disease |
| 000C30 |
B. Lilleeng [Norvège] ; E. Dietrichs [Norvège] | Unmasking psychiatric symptoms after STN deep brain stimulation in Parkinson’s disease |
| 000C87 |
K. Ray Chaudhuri [Royaume-Uni] ; P. Martinez-Martin [Espagne] | Quantitation of non‐motor symptoms in Parkinson’s disease |
| 000C89 |
Susanne Hempel [États-Unis] ; Gill Norman [Royaume-Uni] ; Su Golder [Royaume-Uni] ; Raquel Aguiar-Ibá Ez [Royaume-Uni] ; Alison Eastwood [Royaume-Uni] | Psychosocial interventions for non‐professional carers of people with Parkinson’s disease: a systematic scoping review |
| 000C91 |
Linton J. Meagher [Australie] ; Ralf Ilchef [Australie] ; Paul Silberstein [Australie] ; Raymond J. Cook [Australie] ; Daniel Wasson [Australie] ; Gin S. Malhi [Australie] | Psychiatric morbidity in patients with Parkinson’s disease following bilateral subthalamic deep brain stimulation: literature review |
| 000C95 |
L. Ishihara-Paul [Royaume-Uni] ; N. W. J. Wainwright [Royaume-Uni] ; K. Khaw [Royaume-Uni] ; R. N. Luben [Royaume-Uni] ; A. A. Welch [Royaume-Uni] ; N. E. Day [Royaume-Uni] ; C. Brayne [Royaume-Uni] ; P. G. Surtees [Royaume-Uni] | Prospective association between emotional health and clinical evidence of Parkinson’s disease |
| 000C96 |
A. H. V. Schapira [Royaume-Uni] | Progress in neuroprotection in Parkinson’s disease |
| 000D32 |
A. Probst [Suisse] ; A. Bloch [Suisse] ; M. Tolnay [Suisse] | New insights into the pathology of Parkinson’s disease: does the peripheral autonomic system become central? |
| 000D41 |
R. Myhre [Norvège] ; M. Toft [Norvège] ; J. Kachergus [États-Unis] ; M. M. Hulihan [États-Unis] ; J. O. Aasly [Norvège] ; H. Klungland [Norvège] ; M. J. Farrer [États-Unis] | Multiple alpha‐synuclein gene polymorphisms are associated with Parkinson’s disease in a Norwegian population |
| 000D44 |
J. Kulisevsky [Espagne] ; J. Pagonabarraga [Espagne] ; B. Pascual-Sedano [Espagne] ; A. Gironell [Espagne] ; C. García-Sánchez [Espagne] ; M. Martínez-Corral [Espagne] | Motor changes during sertraline treatment in depressed patients with Parkinson’s disease |
| 000D52 |
Chun-Hung Lin ; Jui-Yen Huang [Taïwan] ; Cheng-Hsin Ching ; Jih-Ing Chuang [Taïwan] | Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone‐induced parkinsonian rats |
| 000D53 |
A. Imamura [États-Unis] ; Y. E. Geda [États-Unis] ; J. Slowinski [États-Unis] ; Z. K. Wszolek [États-Unis] ; L. A. Brown [États-Unis] ; R. J. Uitti [États-Unis] | Medications used to treat Parkinson’s disease and the risk of gambling |
| 000D65 |
Carolyn M. Hutter [États-Unis] ; Ali Samii [États-Unis] ; Stewart A. Factor [États-Unis] ; John G. Nutt [États-Unis] ; Donald S. Higgins [États-Unis] ; Thomas D. Bird [États-Unis] ; Alida Griffith [États-Unis] ; John W. Roberts [États-Unis] ; Berta C. Leis [États-Unis] ; Jennifer S. Montimurro [États-Unis] ; Denise M. Kay [États-Unis] ; Karen L. Edwards [États-Unis] ; Haydeh Payami [États-Unis] ; Cyrus P. Zabetian [États-Unis] | Lack of evidence for an association between UCHL1 S18Y and Parkinson’s disease |
| 000D67 |
X. An [République populaire de Chine] ; R. Peng [République populaire de Chine] ; T. Li [République populaire de Chine, Royaume-Uni] ; J. Burgunder [République populaire de Chine, Singapour] ; Y. Wu [République populaire de Chine] ; W. Chen [République populaire de Chine] ; J. Zhang [République populaire de Chine] ; Y. Wang [République populaire de Chine] ; Y. Xu [République populaire de Chine] ; Y. Gou [République populaire de Chine] ; G. Yuan [République populaire de Chine] ; Z. Zhang [République populaire de Chine] | LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han‐Chinese from mainland China |
| 000D74 |
E. Havlikova [Slovaquie] ; J. Rosenberger [Slovaquie] ; I. Nagyova [Slovaquie] ; B. Middel [Pays-Bas] ; T. Dubayova [Slovaquie] ; Z. Gdovinova [Slovaquie] ; J. P. Van Dijk [Slovaquie, Pays-Bas] ; J. W. Groothoff [Pays-Bas] | Impact of fatigue on quality of life in patients with Parkinson’s disease |
| 000E02 |
Y. J. Zhao [Singapour] ; L. C. S. Tan [Singapour] ; P. N. Lau [Singapour] ; W. L. Au [Singapour] ; S. C. Li [Australie] ; N. Luo [Singapour] | Factors affecting health‐related quality of life amongst Asian patients with Parkinson’s disease |
| 000E17 |
E. Lyros [Grèce] ; L. Messinis [Grèce] ; P. Papathanasopoulos [Grèce] | Does motor subtype influence neurocognitive performance in Parkinson’s disease without dementia? |
| 000E22 |
K. Kwon ; C. G. Choi ; J. S. Kim [Corée du Sud] ; M. C. Lee ; S. J. Chung | Diagnostic value of brain MRI and 18F‐FDG PET in the differentiation of parkinsonian type multiple system atrophy from Parkinson’s disease |
| 000E26 |
M. R. Lemke [Allemagne] | Depressive symptoms in Parkinson’s disease |
| 000E30 |
Darcy Litteljohn [Canada] ; Emily N. Mangano [Canada] ; Shawn Hayley [Canada] | Cyclooxygenase‐2 deficiency modifies the neurochemical effects, motor impairment and co‐morbid anxiety provoked by paraquat administration in mice |
| 000E57 |
L. Bet [Italie] ; S. R. Bareggi [Italie] ; F. Pacei [Italie] ; G. Bondiolotti [Italie] ; G. Meola [Italie] ; A. H. V. Schapira [Royaume-Uni] | Bimodal administration of entacapone in Parkinson’s disease patients improves motor control |
| 000E63 |
K. Wada-Isoe [Japon] ; K. Ohta [Japon] ; K. Imamura [Japon] ; M. Kitayama [Japon] ; T. Nomura [Japon] ; K. Yasui [Japon] ; K. Nakaso [Japon] ; K. Nakashima [Japon] | Assessment of hallucinations in Parkinson’s disease using a novel scale |
| 000F33 |
Charlene Hoffman Snyder [États-Unis] ; Charles H. Adler [États-Unis] | The patient with Parkinson’s disease: Part I–Treating the motor symptoms;Part II–Treating the nonmotor symptoms |
| 000F87 |
A. Wallin [Suède] ; S. Ekberg [Suède] ; K. Lind [Suède] ; V. Milos [Suède] ; A. Granérus [Suède] ; G. Granerus [Suède] | Posterior cortical brain dysfunction in cognitively impaired patients with Parkinson’s disease – a rCBF scintigraphy study |
| 000F88 |
P. Mehta [Australie] ; A. Kifley [Australie] ; J. J. Wang [Australie] ; E. Rochtchina [Australie] ; P. Mitchell [Australie] ; C. M. Sue [Australie] | Population prevalence and incidence of Parkinson’s disease in an Australian community |
| 001033 |
M. Toft [Norvège] ; K. Haugarvoll [Norvège, États-Unis] ; O. A. Ross [États-Unis] ; M. J. Farrer [États-Unis] ; J. O. Aasly [Norvège] | LRRK2 and Parkinson’s disease in Norway |
| 001082 |
H. Matsui [Japon] ; K. Nishinaka [Japon] ; M. Oda [Japon] ; H. Niikawa [Japon] ; T. Kubori [Japon] ; F. Udaka [Japon] | Dementia in Parkinson’s disease: diffusion tensor imaging |
| 001100 |
M. Rentzos ; C. Nikolaou [Grèce] ; E. Andreadou ; G. P. Paraskevas ; A. Rombos ; M. Zoga [Grèce] ; A. Tsoutsou [Grèce] ; F. Boufidou [Grèce] ; E. Kapaki ; D. Vassilopoulos | Circulating interleukin‐15 and RANTES chemokine in Parkinson’s disease |
| 001180 |
M. Sharma [Allemagne] ; J C Mueller [Allemagne] ; A. Zimprich [Autriche] ; P. Lichtner [Allemagne] ; A. Hofer [Allemagne] ; P. Leitner [Allemagne] ; S. Maass [Allemagne] ; D. Berg [Allemagne] ; A. Dürr [France] ; V. Bonifati [Italie] ; G. De Michele [Pays-Bas] ; B. Oostra [Italie] ; A. Brice [France] ; N W Wood [Royaume-Uni] ; B. Muller-Myhsok [Allemagne] ; T. Gasser [Allemagne] | The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson’s disease in European populations |
| 001201 |
V. Dhawan ; D. G. Healy ; S. Pal ; K. Ray Chaudhuri | Sleep-related problems of Parkinson’s disease |
| 001262 |
K A Grosset ; I. Bone ; J L Reid [Royaume-Uni] ; D. Grosset | Measuring therapy adherence in Parkinson’s disease: a comparison of methods |
| 001270 |
Nick Miller [Royaume-Uni] ; Emma Noble [Royaume-Uni] ; Diana Jones ; David Burn | Life with communication changes in Parkinson’s disease |
| 001339 |
D. De Gaspari [Italie] ; C. Siri [Italie] ; A. Landi [Italie] ; R. Cilia [Italie] ; A. Bonetti [Italie] ; F. Natuzzi [Italie] ; L. Morgante [Italie] ; C B Mariani [Italie] ; E. Sganzerla [Italie] ; G. Pezzoli [Italie] ; A. Antonini [Italie] | Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus |
| 001408 |
S. Goldwurm [Italie] ; A Di Fonzo [Italie] ; E J Simons [Pays-Bas] ; C F Rohé [Pays-Bas] ; M. Zini [Italie] ; M. Canesi [Italie] ; S. Tesei [Italie] ; A. Zecchinelli [Italie] ; A. Antonini [Italie] ; C. Mariani [Italie] ; N. Meucci [Italie] ; G. Sacilotto [Italie] ; F. Sironi [Italie] ; G. Salani [Italie] ; J. Ferreira [Portugal] ; H F Chien [Brésil] ; E. Fabrizio [Italie] ; N. Vanacore [Italie] ; A Dalla Libera [Italie] ; F. Stocchi [Italie] ; C. Diroma [Italie] ; P. Lamberti [Italie] ; C. Sampaio [Portugal] ; G. Meco [Italie] ; E. Barbosa [Brésil] ; A M Bertoli-Avella [Pays-Bas] ; G J Breedveld [Pays-Bas] ; B A Oostra [Pays-Bas] ; G. Pezzoli [Italie] ; V. Bonifati [Pays-Bas] | The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor |
| 001411 |
N A Hamid [Royaume-Uni] ; R D Mitchell [Royaume-Uni] ; P. Mocroft [Royaume-Uni] ; G W M. Westby [Royaume-Uni] ; J. Milner [Royaume-Uni] ; H. Pall [Royaume-Uni] | Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement |
| 001418 |
W M M. Schüpbach [France] ; N. Chastan [France] ; M L Welter [France] ; J L Houeto [France] ; V. Mesnage [France] ; A M Bonnet [France] ; V. Czernecki [France] ; D. Maltête [France] ; A. Hartmann [France] ; L. Mallet [France] ; B. Pidoux [France] ; D. Dormont [France] ; S. Navarro [France] ; P. Cornu [France] ; A. Mallet [France] ; Yves Agid [France] | Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up |
| 001442 |
A H V. Schapira | Present and future drug treatment for Parkinson’s disease |
| 001444 |
M. Kliegel [Suisse] ; L H Phillips [Royaume-Uni] ; U. Lemke [Suisse] ; Ute A. Kopp [Allemagne] | Planning and realisation of complex intentions in patients with Parkinson’s disease |
| 001459 |
A F Wright | Neurogenetics II: complex disorders |
| 001460 |
S M Hague [Royaume-Uni] ; S. Klaffke [Royaume-Uni] ; O. Bandmann [Royaume-Uni] | Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease |
| 001482 |
J. Eerola [Finlande] ; P J Tienari [Finlande] ; S. Kaakkola [Finlande] ; P. Nikkinen ; J. Launes [Finlande] | How useful is [123I]β-CIT SPECT in clinical practice? |
| 001508 |
A. Minguez-Castellanos [Espagne] ; F. Escamilla-Sevilla [Espagne] ; M J Katati [Espagne] ; J M Martin-Linares [Espagne] ; M. Meersmans [Espagne] ; A. Ortega-Moreno [Espagne] ; V. Arjona [Espagne] | Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson’s disease: target related effect or selection bias? |
| 001588 |
M G Carpenter [Suisse, Canada] ; J H J. Allum [Suisse] ; F. Honegger [Suisse] ; A L Adkin [Suisse, Canada] ; B R Bloem [Pays-Bas] | Postural abnormalities to multidirectional stance perturbations in Parkinson’s disease |
| 001629 |
M. Martinez [France] ; A. Brice [France] ; J R Vaughan [Royaume-Uni] ; A. Zimprich [Allemagne] ; M M B. Breteler [Pays-Bas] ; G. Meco [Italie] ; A. Filla [Italie] ; M J Farrer [États-Unis] ; C. Bétard [France] ; J. Hardy [États-Unis] ; G. De Michele [Italie] ; V. Bonifati [Italie] ; B. Oostra [Pays-Bas] ; T. Gasser [Allemagne] ; N W Wood [Royaume-Uni] ; A. Dürr [France] | Genome-wide scan linkage analysis for Parkinson’s disease: the European genetic study of Parkinson’s disease |
| 001664 |
Pierre Pollak [France] ; F. Tison [France] ; Olivier Rascol [France] ; A. Destée [France] ; J J Péré [France] ; J M Senard [France] ; F. Durif [France] ; I. Bourdeix [France] | Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up |
| 001678 |
A. Winogrodzka [Pays-Bas] ; P. Bergmans [Pays-Bas] ; J. Booij ; E A Van Royen ; J C Stoof [Pays-Bas] ; E C Wolters [Pays-Bas] | [123I]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease |
| 001735 |
B R Thanvi ; S K Munshi ; N. Vijaykumar ; T C N. Lo | Neuropsychiatric non-motor aspects of Parkinson’s disease |
| 001746 |
N K Patel [Royaume-Uni] ; P. Plaha [Royaume-Uni] ; K. O Ullivan [Royaume-Uni] ; R. Mccarter [Royaume-Uni] ; P. Heywood [Royaume-Uni] ; S S Gill [Royaume-Uni] | MRI directed bilateral stimulation of the subthalamic nucleus in patients with Parkinson’s disease |
| 001774 |
D J Brooks [Royaume-Uni] ; H. Sagar [Royaume-Uni] | Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study |
| 001794 |
P. Mcnamara [États-Unis] ; R. Durso [États-Unis] ; A. Brown [États-Unis] ; A. Lynch [États-Unis] | Counterfactual cognitive deficit in persons with Parkinson’s disease |
| 001822 |
V. S. Kosti ; J. Marinkovi ; M. Svetel ; E. Stefanova ; S. Przedborski [États-Unis] | The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications |
| 001827 |
K R Chaudhuri [Royaume-Uni] ; S. Pal [Royaume-Uni] ; A. Dimarco [Royaume-Uni] ; C. Whately-Smith ; K. Bridgman [Royaume-Uni] ; R. Mathew [Royaume-Uni] ; F R Pezzela [Italie] ; A. Forbes [Royaume-Uni] ; B. Högl [Allemagne] ; C. Trenkwalder [Allemagne] | The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease |
| 001859 |
Kuniaki Tsuchiya ; Kenji Ikeda ; Kazuhiro Niizato ; Sadakiyo Watabiki ; Midori Anno ; Kazuhiro Taki [Japon] ; Chie Haga ; Shuji Iritani ; Masaaki Matsushita | Parkinson’s disease mimicking senile dementia of the Alzheimer type: a clinicopathological study of four autopsy cases |
| 001924 |
D Z Press [États-Unis] ; D J Mechanic [États-Unis] ; D. Tarsy [États-Unis] ; D S Manoach [États-Unis] | Cognitive slowing in Parkinson’s disease resolves after practice |
| 001937 |
G C Pluck [Royaume-Uni] ; R G Brown | Apathy in Parkinson’s disease |
| 001988 |
Stuart Turnbull [Royaume-Uni] ; Brian J. Tabner [Royaume-Uni] ; Omar M. A El-Agnaf [Royaume-Uni] ; Susan Moore [Royaume-Uni] ; Yvonne Davies [Royaume-Uni] ; David Allsop [Royaume-Uni] | α-synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro |
| 001A00 |
V. V. Myllyl ; E. Kultalahti [Finlande] ; H. Haapaniemi [Finlande] ; M. Leinonen [Finlande] | Twelve‐month safety of entacapone in patients with Parkinson’s disease |
| 001A24 |
M. Polatli [Turquie] ; A. Akyol [Turquie] ; O. Çilda [Turquie] ; K. Bayülkem [Turquie] | Pulmonary function tests in Parkinson’s disease |
| 001A84 |
Masashi Kitazawa [États-Unis] ; Vellareddy Anantharam [États-Unis] ; Anumantha G. Kanthasamy [États-Unis] | Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells |
| 001A89 |
S. Thobois [France] ; S. Guillouet [France] ; E. Broussolle [France] | Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson’s disease |
| 001B58 |
A. Björklund [Suède] ; D. Kirik [Suède] ; C. Rosenblad [Danemark] ; B. Georgievska [Suède] ; C. Lundberg [Suède] ; R. J. Mandel [États-Unis] | Towards a neuroprotective gene therapy for Parkinson’s disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model |
| 001B74 |
E. Farina [Italie] ; G. Gattellaro [Italie] ; S. Pomati [Italie] ; E. Magni [Italie] ; A. Perretti [Italie] ; A. P. Cannatà [Italie] ; P. Nichelli [Italie] ; C. Mariani [Italie] | Researching a differential impairment of frontal functions and explicit memory in early Parkinson’s disease |
| 001B84 |
Ken Nakamura [États-Unis] ; Lisa Won [États-Unis] ; Alfred Heller [États-Unis] ; Un Jung Kang [États-Unis] | Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system |
| 001B93 |
Wenbo Zhou [États-Unis] ; Marc S. Hurlbert [États-Unis] ; Jerome Schaack [États-Unis] ; Kedar N. Prasad [États-Unis] ; Curt R. Freed [États-Unis] | Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells |
| 001B95 |
Raúl De La Fuente-Fernández [Canada] ; Asha Kishore [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Nigrostriatal dopamine system and motor lateralization |
| 001B99 |
Stephan P. Swinnen [Belgique] ; Maarten Steyvers [Belgique] ; Lynn Van Den Bergh [Belgique] ; George E. Stelmach [États-Unis] | Motor learning and Parkinson’s disease: refinement of within-limb and between-limb coordination as a result of practice |
| 001C52 |
F. G Kaddis [États-Unis] ; E. D Clarkson [États-Unis] ; K. P Bell [États-Unis] ; P. K Choi [États-Unis] ; C. R Freed [États-Unis] | Co-grafts of muscle cells and mesencephalic tissue into hemiparkinsonian rats: behavioral and histochemical effects |
| 001C65 |
S. Bostantjopoulou [Grèce] ; Z. Katsarou [Grèce] ; D. Zafiriou [Grèce] ; G. Gerasimou [Grèce] ; A. Alevriadou [Grèce] ; G. Georgiadis [Grèce] ; G. Kiosseoglou [Grèce] ; A. Kazis [Grèce] | Abnormality of N30 somatosensory evoked potentials in Parkinson’s disease: a multidisciplinary approach |
| 001D33 |
William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Kelly E. Lyons [États-Unis] ; Alberto Albanese [Suisse] | Surgical treatment of Parkinson’s disease |
| 001D36 |
Rolf Verleger [Allemagne] ; Edmund Wascher [Allemagne] ; Volker Arolt [Allemagne] ; Carola Daase [Allemagne] ; Angelika Strohm [Allemagne] ; Detlef Kömpf [Allemagne] | Slow EEG potentials (contingent negative variation and post-imperative negative variation) in schizophrenia: their association to the present state and to Parkinsonian medication effects |
| 001E50 |
Mark D. Lindner [États-Unis] ; Dwaine F. Emerich [États-Unis] | Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease |
| 001E89 |
Patriciac. Poluha [États-Unis] ; Hans-Leo Teulings [États-Unis] ; Roberth. Brookshire [États-Unis] | Handwriting and speech changes across the levodopa cycle in Parkinson’s disease |
| 001E94 |
B. A. J Veldman [Pays-Bas] ; A. M Wijn [Pays-Bas] ; N. Knoers [Pays-Bas] ; P. Praamstra [Pays-Bas] ; M. W. I. M Horstink [Pays-Bas] | Genetic and environmental risk factors in Parkinson’s disease |
| 001F29 |
Michael L. Selley [Australie] | (E)-4-Hydroxy-2-Nonenal May be Involved in the Pathogenesis of Parkinson’s Disease |
